ISPOR List of Presentations

**ISPOR 21st Annual European Congress, November 2018, Barcelona, Spain**

**MD1**
Evidence Development Timeline of Medical Devices in the UK: Where do MedTech Innovation Briefings Fit?
*Overhill A, Chen G, Upton E, Peirce V, Marsh W*

**PMD167**
Health Technology Assessment of mHealth Applications: Slow Progress in a Fast-Paced Industry?
*Ridley CJA, Tomlinson P, Marsh W*

**PMS66**
Improving Patient and Financial Outcomes in the NHS: Early Arthritis Service Increases Patient Satisfaction Whilst Saving Costs
*Nisar M, Tomlinson P, Taylor C, Beale R*

**PMD134**
Medical Device Appraisal in the UK: What Are the Common Pitfalls of Manufacturer Literature Reviews?
*Macnair P, Marsh W*

**PMD135**
Determining Factors for Decision-Making in the Medical Technologies Evaluation Programme
*Peirce V, Atkinson M, Marsh W*

**PRM109**
Exploring the Use and Acceptance of Alternative Survival Modelling Approaches for Immuno-Oncology Therapies in UK Technology Assessments
*Porteous A, van Hest N, Griffiths M, Morten P*

**MD4**
Evaluating Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison Techniques: Impact on Health-Related Quality of Life of Focussed Ultrasound Thalamotomy and Other Interventions for the Treatment of Medication-Refractory Essential Tremor
*Langford BE, Ridley CJ, Beale RC, Marsh W, Caseby SC, Richard L*

**SY4**
Do EU5 Countries with Favourable Healthcare Expenditure and Reimbursement Indicators have Better Patient Reported Access to Treatments for Rare Diseases?

**PCN201**
No EQ-5D? Analysis of Alternative Utility Value Sources used in NICE Appraisals for Oncology Indications
*Beale RC, Wickstead RM, Chen G, Walker E, Griffiths M*

**PHP3**
Consumer Comments in Health Technology Assessment in Australia: How Common and Influential are They?
*Viswambaram A, McManus K, Miah R, Miles G*

**PHP60**
Health Technology Assessment in Singapore: Shining a Light in the Darkness
*Viswambaram A, Brooks-Rooney C*

**PHP241**
How do NICE Evidence Review Groups Perceive Single Technology Appraisals Presenting Limited Evidence of Comparative Treatment Efficacy?
*Langford BE, Beaver S, Besford M, Castell A, Dierker Viik A, Eddowes LA*

**PHP247**
When the Price is Right: When, in Practice, are Confidential Discounts Introduced in the NICE Process?
*Noon K, Ulrich A, Painter C, Montgomery S*

---

**ISPOR 20th Annual European Congress, November 2017, Glasgow, United Kingdom**

**IP9**
Should Rare Oncology Treatments be Considered True Orphans?
*Griffiths A, Gajraj E, Pantziarka P, Cattaneo I*
An Audit of Evidence Review Group Criticisms of Systematic Literature Reviews Conducted to Inform Manufacturers’ Submissions to the National Institute for Health and Care Excellence
Leonard S, Summers J, Young E

Payers, Politics And Pandemonium: An Insight Into the Future UK Pricing and Market Access Environment
Spoors J, Kusel J

Does the NICE Diagnostics Assessment Programme Use an Empirical ICER Threshold?
Chen G, Koczula KM, Peirce VJ, Marsh W

Model Types Submitted to NICE: What is Considered Appropriate by Evidence Review Groups?
Hearmon NC, Ghosh W, Buguth B, Kusel J

An Exploration of the Methodology of Published Systematic Literature Reviews on “Burden of Disease”
Buchanan-Hughes AM, Beaver S, Fell B, Summers J, Young E

Why do ‘True’ Orphan Medicines Have Such a Low Acceptance Rate When Assessed by the SMC?
Morten P, Ulrich A, Le Fevre R, Eddowes LA

Cost-Effectiveness of PET-CT Versus Adrenal Vein Sampling for the Diagnosis of Hypertension Caused by Primary Aldosteronism
Lin Z, Kusel J, Ghosh W, Brown M

Small and Medium-Sized Enterprises: How Do They Fare in the UK Medical Technologies Evaluation Programme (MTEP)?
Ridley C, Marsh W

---

ISPOR 22nd Annual International Meeting, May 2017, Boston, USA

Value Frameworks to Set Tongues Wagging: Analysis of Opinions and Discussions on Key Value Frameworks

Inequity in Healthcare Access in Asian Countries with Reportedly High Universal Health Coverage Levels
Evans J, Ma C, Noon K, Steeves S

---

ISPOR 19th Annual European Congress, November 2016, Vienna, Austria

How Should Biosimilars be Valued and Should They Undergo Health Technology Assessment?
Kusel J, Psachoulia E, McKenna F, Walker A

Is Off-Label Drug Use Enhancing or Limiting Access for Patients with Rare Diseases?
Griffiths A, Scannell J, Timmis O, Pinilla-Dominguez P

Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: An Exploratory Evaluation Using Advanced Hierarchical Network Meta-Analysis Techniques

Adapting to the Challenge: How are Innovative Study Designs Being Used in Rare Diseases?
Berry L, Eddowes L

Health State Utility Values Measured Using the Euroqol 5-Dimensions Questionnaire in Adults with Chronic Hepatitis C: A Systematic Literature Review
Buchanan-Hughes A, Hanman K, Langford B, Eddowes L
ISPOR 7th Asia-Pacific Conference, September 2016, Singapore

**IP3**
Joint HTA: The Next Step for the ASEAN Economic Community?
Chen G, Ngorsurachet S, Redekop K

**IP15**
Should Productivity Losses due to Illness be Considered in Health Economic Evaluations?
Brooks-Rooney C, Redekop K, Wee HL, Milea D

**PCV33**
Measurement of Adherence to Anti-Hypertensive Drugs in Asia
Ma Q, Kao C, Miles G, Chen G

**PCV54**
Quantifying Informal versus Formal Care, and Financial Caregiver Burden, for Stroke Patients in Asia: A Structured Literature Review
Wayman S, Langford B, Buchanan-Hughes A, Chen G

**PHP38**
Universal Health Coverage in Countries across East and South East Asia – Associations between Health Expenditure and Service Provision
Evans J, Wickstead R, Hanman K, Steeves S

**PIN15**
Economic Burden of Antibiotic-resistant Nosocomial Gram-Negative Bacteraemia in Singapore Hospitals
Chen G, Lim S, Ma Q, Kao C, Ghosh W

**PMD23**
Cost of Ebola Virus Disease Diagnosis Using Rapid Point-of-Care Diagnostics in Sierra Leone
Evans J, Hearmon N, Beale R, Marsh W

**PMD59**
Investigating the Cost-Effectiveness of Genetic Counselling for Couples at Known Risk of Having Children with Tay-Sachs Disease: A Two-Generation Model
Ghosh W, Griffiths M, Griffiths A
The Trade-Off Between QALY Maximisation and Social Values: A Systematic Review of Public Opinion Surveys

*Buchanan-Hughes A, Kusel J*

---

Does Budget Impact Affect Reimbursement Decisions Made by the Cancer Drugs Fund in England?

*Stewart G, Kusel J, Montgomery S*

---

Investigating the Cost-Effectiveness of Bacterial Whole-Genome Sequencing for Enabling Targeted Antibiotic Selection in Urinary Tract Infections

*Buchanan-Hughes A, Griffiths A, Evans J, Slater D, Eddowes L*

---

The Role of Education in the Management of Type 1 Diabetes Mellitus in England

*Toth C, Marsh W, Stewart G, Yang L, Bridges H, Kusel J*

---

Using Incentives to Improve Health-Related Behaviours: A Review of Incentive-Based Trials

*Bunting C, Lim S, Morten P*

---

Development of a PRECIS-2 Scoring Grid: How Pragmatic are Pragmatic Trials of Surgical and Pharmaceutical Interventions?

*Chen G, Ma Q, Yang L, Ghosh W, Kusel J*

---

Hunting for Randomised Controlled Trials (RCTs): A Comparison of Search Filters Designed to Identify RCTs

*Steeves S, Buchanan-Hughes A, Evans J, Leonard S*
Economic Orphans? The Prevalence of Child-specific Utilities in NICE Appraisals for Paediatric Indications
Montgomery S, Hassan M, Kusel J

Predicting the Impact of Value-based Assessment on Future NICE Appraisals
Beale RC, Maruszczak M, Kusel J

A Cost of Care Model for Inflammatory Bowel Disease with a UK NHS Perspective
Miles G, Leonard SA, Ghosh N, Premchand P

Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis
Maruszczak M, Kusel J, Adlard N

Antidepressant Use and Suicide Rate in England: The Geographic Divide
Anderson R, Wilson T, Griffiths M

Discrete Event Simulation for the Cost-effectiveness Evaluation of PET-CT Scans in the Diagnosis of Conn’s Disease in Hypertensive Patients
Maruszczak M, Stewart G, Kusel J, Brown MJ

Systematic Review and Critique of Health Economic Models of Relapsing-remitting Multiple Sclerosis in the UK
Kusel J, Maruszczak M, Montgomery S, Allen F, Adlard N

Investigating the Use of Personalised Medicine in Cancer Trials – An Update
Hamilton K, Wilson T
### ISPOR 6th Asia-Pacific Conference, September 2014, Beijing, China

**IP2**
Disinvestment in Asia-Pacific: How Can This Be Implemented in HTA and What Can Be Learnt from Europe?
*Brooks-Rooney C, Kamae I, Tan ST, Gutiérrez-Ibarluzea I*

**QA2**
An Analysis of New Health Technologies and Reimbursement Pricing Structure in Taiwan
*Stewart G, Brooks-Rooney C*

**PCN13**
Analysing the Effects of a Disinvestment Decision in Breast Cancer Screening Programmes in Asia-Pacific Countries: A Modelling Approach
*Agirrezabal I, Bunting C, Brooks-Rooney C*

**PCN39**
The Differences Between Cancer Drug Approvals in Japan and the USA
*Anderson R, Brooks-Rooney C*

**PDB9**
Impact of Ethnicity on the Efficacy and Safety Outcomes of Anti-Diabetes Drugs – Case Study of Liraglutide in Asian and Non-Asian Populations
*Chen G, Yang L, Lantaff B, Kusel J, Warnakula S, Brooks-Rooney C*

**PMS30**
Closing the Gap: Reduced Delay to Drug Marketing Approval Between the West and Asia
*Hamilton KI, Eddowes LA, Brooks-Rooney C*

**PIN33**
The Differences Between Infectious & Parasitic Drug Approvals in Japan and the USA
*Anderson R, Brooks-Rooney C*

### ISPOR 16th Annual European Congress, November 2013, Dublin, Ireland

**IP13**
Should Off-Label Agents Be Used as Comparators in Health Technology Assessments?
*Kusel J, Walker W, Spackman E, Andersson C*

**PCN207**
Impact of Recommended Pharmaceuticals on Cancer Mortality: Analysis of Real-Life Data
*Wilson T, Hamerslag L, Kusel J*

**PHP152**
The Relationship Between Scientific Research, Clinical Trials and FDA Drug Approval
*Burgon J, Hamerslag L*

**PHP166**
How Does the Uncertainty Around the Expected ICER Affect NICE Decisions?
*Barber R, Steeves S, Wilson T, Hamerslag L, Kusel J*

**PMH68**
How Well Do We Understand the Economic Burden Associated with Dementia? A Focus on Trends in Care Home Costs and Future Perspectives in the UK
*Griffiths M, Hamerslag L, Wilson T, Stewart G, Kusel J*

**PMS27**
Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs
*Miles G, Bell J, Wilson T, Hamerslag L, Kusel J*
ISPOR 18th Annual International Meeting, May 2013, New Orleans, USA

PSY89
Treatment Options in Obesity: Is Clinical Development Keeping up with an Expanding Population?
Hay J, Barber R, Kusel J, Wilson T

PRM11
The Use of Biomarkers in Cancer Trials in Asia
Hamerslag L, Wilson T, Brooks-Rooney C

ISPOR 17th Annual International Meeting, June 2012, Washington DC, USA

PCN148
The Use of Personalised Medicine in Cancer Trials

PHP66
Assessing Agreement Between Patient Access Schemes: Review of NICE and SMC Guidance
Timm B, Leonard S, Haynes S

ISPOR 15th Annual European Congress, November 2011, Madrid, Spain

RS2
Hamerslag L, Haynes S, Kusel J, Costello S

PRM11
The Rise of Budget Impact Analyses – Another Hurdle in the Health Technology Approval Process?
Wong GKW, Hamer N, Wilson T, Costello S

ISPOR 14th Annual European Congress, November 2012, Berlin, Germany

PCN144
Access to Cancer Interventions Across the UK: To What Extent Does SMC Advice Agree with NICE’s End-of-Life Therapies?
Hamerslag L, Brooks-Rooney C, Zhou A, Pettit L

CA2
Applying a Value-Based Price Across Different Disease Areas
Wilson TJ, Kusel J, Brooks-Rooney C, Costello S

PHP104
Assessing the Implementation of NICE Guidance: Is There a Correlation Between Recommendations and Uptake in Clinical Practice

ISPOR 5th Asia-Pacific Conference, September 2012, Taipei, Taiwan

PMS48
Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know?
Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J

PSY89
The Characteristics of Clinical Trials in Asia
Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S

PRM11
The Use of Personalised Medicine in Cancer Trials in Asia
Hamerslag L, Wilson T, Brooks-Rooney C

ISPOR 15th Annual European Congress, September 2012, Taipei, Taiwan

PH82
The Characteristics of Clinical Trials in Asia
Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S

PRM11
The Use of Biomarkers in Cancer Trials in Asia
Hamerslag L, Wilson T, Brooks-Rooney C

IIOR 14th Annual International Meeting, New Orleans, USA

NI2
The Use of Off-Label Comparators in NICE Appraisals – An Indirect Endorsement?
Kusel J, Wong GK, Hay JA, Pettit LJ

PCN148
The Use of Personalised Medicine in Cancer Trials

ISPOR 15th Annual European Congress, November 2012, Berlin, Germany

PMS48
Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know?
Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J

PHP123
To What Extent Does Advice From the SMC Agree with that Published by NICE?
Leonard SA, Brooks-Rooney C, Kusel J, Costello S

Costello Medical Consulting Ltd
PHP145
The Burden of Evidence in the Pharmaceutical Appraisal Process

PHP152
The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study

PRM9
What Guidance is Available for Budget Impact Analysis?
Kusel J, Leonard S, Wilson T, Costello S

ISPOR 16th Annual International Meeting, May 2011, Baltimore, MD, USA

PRM3
The Burden of Caregiving: Assessing the Status of Current Clinical Research
Hamer N, Costello S, Hamerslag L, Haynes S, Roper S

PHP5
Incentive-based Interventions – Rewarding Patients for Good Behaviour
Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP7
Kusel J, Hamer N, Roper S, Hamerslag L, Costello S

PHP43
The Influence of Patient Access Schemes on Appraisal Decisions by NICE in the UK

PHP89
The Implementation of Public Health Guidance: Preference for Clinical over Behavioural Interventions
Hamerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S

PMS69
The Use of Mixed Treatment Comparisons in NICE Technology Appraisals

ISPOR 13th Annual European Congress, November 2010, Prague, Czech Republic

NI4
Do Patient Access Schemes Result in an Acceptable Administrative Burden?
Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP94
Is it Cost-Effective to Change the Behaviour of Healthcare Professionals?

PHP98
Cost-Effectiveness Methodologies of Strategies that Aim to Change the Behaviour of Healthcare Professionals

ISPOR 15th Annual International Meeting, May 2010, Atlanta, GA, USA

PHP79
Innovative Pricing Agreements in UK NICE Submissions
Costello S, Haynes S, Kusel J, Brooks-Rooney C, Hamer N